Hemodialysis and peritoneal dialysis patients develop a high antibody response when completing the Covid-19 vaccination schedule, reducing hospitalizations and deaths from the disease.
This was explained by the Spanish specialist Marian Goicoechea, when presenting the subject of Covid-19 in patients on hemodialysis in Spain, where she released the results of studies carried out in patients with chronic kidney disease, where it was shown that they develop a high antibody response to 28 days after the second dose is placed.
The international expert referred to the issue while participating in the XII National Congress of Nephrology, XX Dominican Spanish Course and III Central American and Caribbean Transplant Meeting, held by the Dominican Society of Nephrology specialized in the country with the participation of national and foreign experts .
He pointed out that patients with kidney failure who receive hemodialysis treatment are vulnerable to becoming seriously ill due to Covid-19, which is why they are being included for the placement of a third dose of vaccine against the virus, with very good results.
He said that preliminary studies indicate that all those vaccinated developed antibodies after 28 days of placing the second dose without difference of sex, and that in transplanted patients the response is lower.
He pointed out that in Spain a third dose is being given to both hemodialysis and transplant patients and that studies have shown that the response is greater after a third dose.
He said that it is evident that the mortality of kidney patients is very high when they get sick from Covid-19, so the vaccine is an important preventive measure.
The scientific activity that concludes this Sunday brings together specialists from different countries, where the main problems that affect kidney patients, the advances and novelties of the treatments and the situation of kidney transplantation are discussed.
It also includes discussions on high blood pressure and kidney damage, patients on hemodialysis, risk stratification in the critically ill patient in the Dominican Republic and new treatments to reduce cardiovascular risk in kidney patients, among other topics.
– .
